Literature DB >> 12352625

S100B is increased in mood disorders and may be reduced by antidepressive treatment.

Matthias L Schroeter1, Hashim Abdul-Khaliq, Albert Diefenbacher, Ingolf E Blasig.   

Abstract

Previous studies have reported alterations of glial cells and particularly astrocytes in mood disorders. Therefore, serum concentration of the astrocytic marker S100B was ascertained with an immunoluminometric assay in 20 patients with mood disorder and 12 healthy age-matched controls. Serum S100B was elevated in major depression (median after admission 410 ng/l, at discharge < 100 ng/l) and mania (130, 160 ng/l), when compared with controls (< 100 ng/l; rho< 0.01). Antidepressive treatment reduced S100B in conjunction with severity of depressive symptoms ( rho< 0.01). The severity of depression (Hamilton Depression Rating Scale) was positively correlated with S100B (r(s) = 0.51, rho< 0.005). Elevated serum S100B during depressive and manic episodes of mood disorders may indicate alterations of astrocytes, which are reversed by antidepressive treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352625     DOI: 10.1097/00001756-200209160-00021

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  37 in total

1.  Chronic fluoxetine treatment changes S100B expression during postnatal rat brain development.

Authors:  Nathalie Bock; Emre Koc; Hannah Alter; Veit Roessner; Andreas Becker; Aribert Rothenberger; Till Manzke
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-09-11       Impact factor: 2.576

2.  Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.

Authors:  Emilio L Streck; Gislaine T Rezin; Luciana M Barbosa; Lara C Assis; Eliane Grandi; João Quevedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-03       Impact factor: 3.000

3.  S100B blood levels and childhood trauma in adolescent inpatients.

Authors:  Tatiana Falcone; Damir Janigro; Rachel Lovell; Barry Simon; Charles A Brown; Mariela Herrera; Aye Mu Myint; Amit Anand
Journal:  J Psychiatr Res       Date:  2014-12-25       Impact factor: 4.791

4.  S100beta protein expression: gender- and age-related daily changes.

Authors:  M I Nogueira; S Y Abbas; L G M Campos; W Allemandi; P Lawson; S H Takada; E C Azmitia
Journal:  Neurochem Res       Date:  2009-02-11       Impact factor: 3.996

Review 5.  Neurobiology of resilience in depression: immune and vascular insights from human and animal studies.

Authors:  Katarzyna A Dudek; Laurence Dion-Albert; Fernanda Neutzling Kaufmann; Ellen Tuck; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2019-09-13       Impact factor: 3.386

6.  Retinal Nerve Fiber Layer Thickness Measurement by Spectral-Domain Optical Coherence Tomography in Patients with Major Depressive Disorder.

Authors:  İpek Sönmez; Ferdi Köşger; Ümit Aykan
Journal:  Noro Psikiyatr Ars       Date:  2017-03       Impact factor: 1.339

7.  The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.

Authors:  Kun Yang; Guang-Rong Xie; Yi-Qiu Hu; Fu-Qiang Mao; Lin-Yan Su
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

8.  Mood disorders are glial disorders: evidence from in vivo studies.

Authors:  Matthias L Schroeter; Hashim Abdul-Khaliq; Julia Sacher; Johann Steiner; Ingolf E Blasig; Karsten Mueller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-05-27

9.  Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.

Authors:  Lee A Shapiro; Lynn A Bialowas-McGoey; Patricia M Whitaker-Azmitia
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-22

10.  Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response.

Authors:  Byong-Su Jang; Hyeran Kim; Shinn-Won Lim; Ki-Won Jang; Doh-Kwan Kim
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.